Information Provided By: 
Fly News Breaks for March 19, 2018
AXGN
Mar 19, 2018 | 08:22 EDT
Jefferies analyst Raj Denhoy raised his price target for AxoGen to $45 after meeting last week with the company's CEO and CFO. The recent rally in the shares as well as "significant appreciation from here seems well justified," Denhoy tells investors in a research note. He puts AxoGen "right at the top" of the growth stories in all of medtech given its "big underpenetrated markets, unique technologies, growing surgeon acceptance, and no real competition." Denhoy keeps a Buy rating on the shares.
News For AXGN From the Last 2 Days
There are no results for your query AXGN
